The dopamine D2 receptor was not present in the 30 meningiomas examined for this. These findings indicate that the dopamine D~ receptor identified is expressed alone and is therefore regulated independent of a D2 receptor in cerebral meningioma tissue. Although the function of the dopamine D~ receptor in cerebral meningiomas has not so far been defined, previous studies have suggested that the D~ receptor might be involved in the control of proliferative growth of meningiomatous tissue.
W
E have recently reported that the estrogen receptor protein is not expressed in meningioma tissue and that a high percentage of the progesterone receptor protein in cerebral meningiomas may actually be present in an inactive form. 33 This was supported by cell culture experiments ~ as well as by clinical studies) 3 However, there are preliminary reports indicating that the antiprogestogenic agent RU-486 (mifepristone) may have an antiproliferative effect in meningiomatous tissue. This conclusion was based on selected results in cultured meningioma tissue 28 and in meningioma tissue transplanted into nude mice. 29 Recently, mifepristone was observed to be effective in patients with unresectable meningiomas. ~~ During the past few years, other mitogenic factors and their related receptors (epidermal growth factoP g and its receptorfl 7'49 insulin-like growth factor I ~7' 48 and its receptor, ~7 fibroblast growth factor, 48 and the messenger ribonueleic acid of platelet-derived growth factor and its receptor 2~ were reported to be present in or to act on meningioma tissue.
We have recently reported that dopamine and dopaminergic agents inhibit cell proliferation in cerebral meningiomas in culture. 34 The catecholamine dopamine is known to have inhibitory activity on cell growth. This effect is documented for malignant cell proliferation in tissue of neuronal origin (human retinoblastoma ~9 and mouse neuroblastoma cells:'~ but also in melanomas 5~ and pituitary adenomas) 4 In this study, we report the presence of high-affinity dopamine D, receptors in a series of cerebral meningiomas by saturation and Scatchard analyses and by rank order of competition curves for dopaminergic and related agents.
Materials and Methods

Tissue Selection
Tumor specimens from 45 patients with cerebral meningiomas were used in this study. All tumors were intracranial and six were recurrent meningiomas. The histological classification of the resected tumors was (Table 1) . These 45 tumors were used for the dopamine D~ receptor assay, and 30 tumors were used in parallel for the dol0amine D2 receptor assay. At the time of surgery, seven women (mean age 43.8 years) were premenopausal and 21 women (mean age 62.9 years) were postmenopausal; the remaining 17 patients were men. The ratio of women (28 patients, mean age 58.1 years) to men (17 patients, mean age 60.7 years) was 1:1.65. All patients received dexamethasone before and during surgery.
Membrane Preparation
Resected meningioma tissue from each patient was immediately snap-frozen in liquid nitrogen and stored at -80"C until processing. No specimen was stored longer than 4 months. Tumor samples (about 300 mg wet weight per assay) were thawed to 2 ~ to 4"C and homogenized in 2 ml ice-cold buffer using 10 up-anddown strokes with a Teflon pestle rotating at 1000 rpm.
This was done three times with a 10-second immersion each time in an ice bath. Homogenization of the tissue using a polytron resulted in a loss of receptor density (Bm~0 of up to 50%. The dissociation rate constant (Kd) was not altered (data not shown). This loss of receptor density by polytron homogenization is in agreement with the experience of others. 27 The tissue homogenate was transferred to a plastic tube and centrifuged for 15 minutes at 800 G and 4~ The supernatant, including the membrane fraction, was centrifuged for 30 minutes at 30,000 G and 4~ The membrane pellet was resuspended in 4 ml of buffer and kept on ice until used in the assay. The buffer used for homogenization and incubation consisted of (in raM): Tris-HCl 50, NaC1 120, ethylenediamine tetra-acetic acid 1, KCI 5, CaCI2 1.5, and MgC12 4. The presence of magnesium is essential for optimizing the saturation and competition curves, and yields an optimum B .... 9 All studies were performed on fresh membrane preparations since frozen membrane fractions have a remarkable loss of receptor density (up to 40% after thawing).
Membrane Receptor Assay
To characterize the dopamine DI receptor, we used the dopamine D~ antagonist [~2~I]SCH-23982 as ligand.* For saturation analysis, increasing amounts of the iodinated tracer were used ranging from 1.25 pM to 1.2 nM. We used a 10-point assay (10 different and increasing concentrations, each in duplicate). To determine the nonspecific binding, 1 uM (+)-butaclamol was used in a parallel assay. The assays were started with aliquots of prepared membranes (see above) and incubated at room temperature for 45 minutes. The total volume of each point was 500 #1 in Eppendorf cups. Stereoselectivity was determined by the inactive isomers (-)-butaclamol, a dopamine antagonist, and by (-)-SKF-38393, a selective dopamine D1 agonist.
After the equilibration period, the membranes were pelleted and the assay terminated by centrifugation (13,000 G). The fluid supernatants were aspirated and the tips of the Eppendorf cups containing the membrane pellet were cut off to reduce the background. The tracer bound to the membrane pellet (total and unspecific binding) was then counted in a gamma counter with 70% efficiency.t
The assays for the dopamine D2 receptor were carried out in the same way as described above using the selective dopamine D2 ligand ['25I]4-iodo Spiperone.~ Saturation analysis was carried out with amounts of the ligand ranging from 1.25 pM to 3 nM. 
Protein Assay
Total protein was measured in the membrane preparation ready for the binding assay and expressed as mg protein/ml. The protein content of the pellets was determined with a microprotein assay, with protein concentrations ranging from 0.06 to 0.08 mg per tube (the final concentrations of membrane pellet protein in each Eppendorf cup).
Association and Dissociation Rate Constant
For both the association and dissociation rate constants, the dopamine D~ tracer [J25I]SCH-23982 was used in a concentration according to the K~ (250 pM). To determine the association rate constant, the reaction (buffer and [~25I]SCH-23982) was started with membrane aliquots and terminated by centrifugation after 2, 4, 8, 10, 20, 40, or 60 minutes. To determine the dissociation rate constant, the reaction (buffer, membranes, and [J-'5I]SCH-23982) was started and, after equilibrium was reached (about 20 minutes), 500 nM unlabeled SCH-23390 was added and the reaction stopped with a time delay of (0), 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 20 minutes, and counted as described above,
Competition Curves
For competition experiments, the dopamine D~ tracer [~-~-~I]SCH-23982 was also used in a concentration of 250 pM. Increasing concentrations of dopaminergic agents ranging from 10 -~t to 10 -4 M were used as competitors. The competitors used were: the selective dopamine D~ antagonists (+)-SCH-23390 and (_+)-SKF-83566; the nonselective dopamine antagonists (cis)-flupentixol, (+)-butaclamol, (-)-butaclamol, and chlorpromazine; the selective dopamine D2 antagonist 1-sulpirid; and the serotonin (5-hydroxytryptamine, 5-HT) antagonist mianserin (5-HT2 > 5-HT0.w After equilibration for 45 minutes, the reactions were stopped and counted as described above.
Guanyl-5'-yl Imidodiphosphate Testing
Membranes of meningiomas that were positive for dopamine D~ receptors were incubated with 250 pM [~2sI]SCH-23982. Increasing concentrations (10 -~ to 10 -4) of dopamine antagonists ((+)-butaclamol or SCH-233901 were used in the presence and absence of 200/ 400 (guanyl-5'-yl imidodiphosphate (Gpp(NH)p)). Samples were incubated for 30 minutes at 37"C or for 45 minutes at room temperature.
Data Analysis
Binding data for saturation curves and Scatchard transformation were analyzed with the computer-directed program Enzfitter. Data from association and dissociation studies were analyzed with a curve-fitting program. Competition curves were analyzed with Graphpad, a computer-assisted curve-fitting program, II 
Results
Dopamine D1 Receptor Saturation Analysis
The binding of [~25I]SCH-23982 was saturable ( Fig.  1 ) and the Scatchard transformation was linear (Fig. 1  inset) (Fig. 1) . For the 45 meningiomas examined, 33 were positive for the dopamine D~ receptor. In the remaining 12 meningiomas, the dopamine D~ receptor could not be detected.
Dopamine De Receptor
None of the 30 cerebral meningiomas tested, which included both dopamine D~-positive and -negative tissue, were positive for the dopamine D2 receptor. Rat frontal cortex, used as control tissue, exhibited dopamine D2 receptors with a K~ of 216 pM and a Bmax of 234 fmol/mg membrane protein.
Association Rate and Dissociation Rate Constant
Association experiments revealed that [~2sI]SCH-23982 binding to the dopamine D~ receptor reached equilibrium within 7 minutes at room temperature. The association rate constant (k + 1) was calculated to (Fig. 2 left) .
Dissociation experiments revealed that [~25I]SCH-23982 binding to the dopamine DI receptor is completely reversible after 10 minutes using unlabeled SCH-23982. The dissociation rate constant (k -1) was calculated to be 0.389 nM -~ x rain -x with a half-time of dissociation of 1.78 minutes (Fig. 2 right) . Both calculations were made with Graphpad Inplot software. 
Guanyl-5'-yI Imidodiphosphate Testing
The nonhydrolyzable guanosine triphosphate analogue Gpp(NH)p converts the high-affinity state of many receptors coupled to G proteins to the low-affinity state. 39 In our experiments, the presence of 200 ~M or even 400 uM of Gpp(NH)p did not change the competition binding characteristics significantly by displacing the dopamine antagonists SCH-23390 or (+)-butaclamol. This experiment was performed twice with two different dopamine D~ receptor-positive meningiomas. The IC~ value (the concentration that competes for 50% of specific binding) of one exemplary meningioma using the dopamine antagonist SCH-23390 was 3.48 x 10 -~ without Gpp(NH)p and 4.24 • 10 -s in the presence of Gpp(NH)p.
Competition Curves
It has been reported that [125I]SCH-23982 binds to 5-HT2 receptors. Therefore, we had to investigate the pharmacology of [JzsI]SCH-23982 binding sites in respect to dopaminergic and serotonergic competitors in meningioma tissue. The competitors employed inhibited the [~251]SCH-23982 binding sites in a concentration-dependent and stereoselective manner (Fig. 3) . Dopamine antagonist and serotonin antagonist competition curves were monophasic, thus supporting the presence of a homogeneous population of receptor sites. Table 2 and Fig. 3 ). The IC50 values of all competitors are listed in Table 2 .
Discussion
Classification of Dopamine Receptors and Signal Transduction Pathways
Neural dopamine receptors have been divided into different classes, named D 1 through D5.4'6' 15.41-43.45,53 The dopamine D~ receptor is classically known to be positively coupled to the cyclic adenosine monophosphate system stimulating the enzyme adenylate cyclase, n54~ whereas activation of the dopamine D2 receptor leads to various responses 44 that mainly inhibit this enzyme. 3' 7 However, in human frontal cortex, dopamine-binding to dopamine DL receptors failed to induce adenylate cyclase. 8 In addition, different forms of dopamine D~ receptors (subclassified into D~A and D~B), which are linked to different signal-transduction pathways, may exist. 24 This assumption was confirmed when two separate D~ receptor proteins, linked either to adenylate cyclase or to the activation of phosphatidylinositolspecific phospholipase C, were identified in the rat striatum, 18 providing evidence for molecular heterogeneity of the dopamine Dj receptor.
Guanine Nucleotide Binding
Guanine nucleotide binding results in the uncoupling of many receptor types from G proteins, thus decreasing the affinity of the receptor for its agonist. 3L39 The ability of these high-affinity binding sites to be converted to low-affinity binding sites by the guanylnucleotide Gpp(NH)p suggests that they are tightly and specially coupled to G proteins. Our data prove that the dopamine Dz receptor in cerebral meningiomas is not coupled to a G protein, which is indicated by the fact that 200 #M or even 400 uM Gpp(NH)p failed to cause a shift in the competition curves. These results concurred with those of a dopamine D~ receptor found in the rat frontal cortex 8 and bovine pineal gland, 39 as well as with the recently published sequence of a nonguanine U. M. H. Schrell, P. Nomikos, and R. Fahlbusch nucleotide-sensitive low-affinity form of a human dopamine D~ receptor. 42 
Scatchard Analysis
Our results provide convincing evidence that [J25I]-SCH-23982 binding sites in cerebral meningioma tissue are dopamine D~ receptors. Due to their pharmacological properties, the dopamine D~ receptors described here behave like [3H]SCH-23390 binding sites in the striatum, ~1' -' 6 bovine pineal gland, -~9 and parathyroid gland. 25 The mean dissociation rate constant (K~) of 369 pM using [L~sI]SCH-23982 as ligand is completely comparable to that from other tissues examined? 5,37 Concerning the receptor density (Bmax), the mean value of 31.9 fmol/mg membrane protein is lower compared to other tissues. 11.25.26,39,52 Although the mean receptor density is 31.9 fmol/mg membrane protein, it is unlikely that this density is due to the content of blood vessels in the tumor tissue. The absence of dopamine D2 receptors in all meningiomas and of D~ receptors in a minor group supports the latter contention.
Competition Curves
The Table 2 agree well with their affinities determined for striatal dopamine D1 receptors? With this well-defined rank order for the competitors used, the evidence for the identity of a dopamine DI receptor in cerebral meningiomas is compelling.
Physiology of the Dopamine D~ Receptor
The physiological properties of the dopamine Dj receptor are insufficiently defined to date. Stimulation of the D~ receptor is coupled with behavioral effects z46 and is known to have a modulatory influence on the activity of the D2 receptor and vice versaY Furthermore, the dopamine Dj receptor may also be a primary site of therapeutic action of neuroleptic drugs. 2~
In striatal tissue, the dopamine DI receptor is not associated with the dopamine D2 receptor. This suggests that the dopamine D~ receptor may have functions not coupled to and therefore independent from the dopamine D2 receptor. ~ 1
Dopaminergic Agents and Cell Growth
The catecholamine dopamine inhibits malignant celI proliferation in vitroJ 9'22"3~ This effect of dopamine, and also of other catecholamines, was attributed to the auto-oxidation of quinones, leading to cytotoxicity. J6'~ By minimizing the toxic effect of auto-oxidation products with ascorbic acid, Prasad 3~ recorded significant growth inhibition in a mouse neuroblastoma cell population by dopamine and 6-hydroxydopamine in micromolar concentrations, whereas in hamster ovary cells these compounds were ineffective. Other groups have recently reported the presence of dopamine D~ and/or D2 membrane receptors in neuroblastoma and retinoblastoma cell lines. 23 '36 We have found that dopaminergic agents, especially selective dopamine D1 agonists, inhibit growth of cultured cerebral meningiomas. 34 We have postulated that this antiproliferative effect may be regulated by membrane dopamine Dj receptors. 34 In contrast, other authors have reported high-affinity binding sites for [3H]dopamine in the cytosol and nuclear fraction of y-79 retinoblastoma cells, which may also be a site of dopaminergic action. ~9
Conclusions
This study provides evidence for the presence of dopamine D, receptors and the absence of dopamine DE receptors in cerebral meningioma tissue. The presence of dopamine D, receptors is based on the dissociation rate constant (K~), the maximum capacity (Bmax), and kinetic studies (saturation curves, Scatchard analysis, association and dissociation rate constants, and displacement curves according to their rank order).
Recently, we have found that dopaminergic agents are involved in the control of the proliferative growth of cultured meningiomatous tissue. 32'34 Although the mechanism of action has not yet been determined, it is conceivable that patients with recurrent and unresectable meningiomas will benefit from an antiproliferative therapy with dopaminergic agents, especially with selective dopamine D~ agonists.
